Serotonin function in pathological gambling: Blunted growth hormone response to Sumatriptan

Stefano Pallanti, Silvia Bernardi, Andrea Allen, Eric Hollander

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Pathological gambling is a disruptive behaviour and an important public health concern that is classified as an impulse control disorder, and is also conceptualized as a prototype of 'behavioural addiction'. Its phenomenology cannot be reduced to a single neurobiological dysfunction; instead, it has been conceived as a complex chain of events in which the serotonergic system (5-HT) has often been suggested as one of the most prominent involved. Acute administration of Sumatriptan, a selective 5-HT1B/1D agonist, has been used to investigate the functional responsivity of 5-HT1B/1D receptors in alcoholics, resulting in a blunted growth hormone response. These findings have been interpreted as being due to the down-regulation of these receptors. However, previous studies could not rule out the possibility that the changes in receptor function were induced by chronic substance exposure. Twenty-two pathological gamblers and 19 healthy control subjects were evaluated in response to double-blind administration of both a single dose of oral Sumatriptan (100 mg) and of placebo in a crossover design. All participants were screened to ensure that they were negative for lifetime alcohol and drug addiction, and had been free of substance abuse for at least 6 months. Outcome measures included growth hormone, prolactin, gambling severity, mood, craving and 'high' change scales. A blunted growth hormone response was observed in pathological gamblers compared with healthy controls after Sumatriptan administration. No statistically significant differences were found for prolactin or behavioural measures, except for an increase in anxiety over time in pathological gamblers. These results, together with those obtained in our previous serotoninergic challenge study, document the presence of a serotonergic dysfunction in pathological gamblers similar to that reported in alcoholics.

Original languageEnglish (US)
Pages (from-to)1802-1809
Number of pages8
JournalJournal of Psychopharmacology
Volume24
Issue number12
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Sumatriptan
Gambling
Growth Hormone
Serotonin
Alcoholics
Prolactin
Substance-Related Disorders
Disruptive, Impulse Control, and Conduct Disorders
Receptor, Serotonin, 5-HT1B
Serotonin 5-HT1 Receptor Agonists
Cross-Over Studies
Alcoholism
Healthy Volunteers
Down-Regulation
Anxiety
Public Health
Placebos
Outcome Assessment (Health Care)

Keywords

  • 5-HT1B/1D
  • alcohol
  • craving
  • gambling
  • growth hormone
  • Sumatriptan

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Serotonin function in pathological gambling : Blunted growth hormone response to Sumatriptan. / Pallanti, Stefano; Bernardi, Silvia; Allen, Andrea; Hollander, Eric.

In: Journal of Psychopharmacology, Vol. 24, No. 12, 12.2010, p. 1802-1809.

Research output: Contribution to journalArticle

Pallanti, Stefano ; Bernardi, Silvia ; Allen, Andrea ; Hollander, Eric. / Serotonin function in pathological gambling : Blunted growth hormone response to Sumatriptan. In: Journal of Psychopharmacology. 2010 ; Vol. 24, No. 12. pp. 1802-1809.
@article{2f620b1925e547468924735896288a5e,
title = "Serotonin function in pathological gambling: Blunted growth hormone response to Sumatriptan",
abstract = "Pathological gambling is a disruptive behaviour and an important public health concern that is classified as an impulse control disorder, and is also conceptualized as a prototype of 'behavioural addiction'. Its phenomenology cannot be reduced to a single neurobiological dysfunction; instead, it has been conceived as a complex chain of events in which the serotonergic system (5-HT) has often been suggested as one of the most prominent involved. Acute administration of Sumatriptan, a selective 5-HT1B/1D agonist, has been used to investigate the functional responsivity of 5-HT1B/1D receptors in alcoholics, resulting in a blunted growth hormone response. These findings have been interpreted as being due to the down-regulation of these receptors. However, previous studies could not rule out the possibility that the changes in receptor function were induced by chronic substance exposure. Twenty-two pathological gamblers and 19 healthy control subjects were evaluated in response to double-blind administration of both a single dose of oral Sumatriptan (100 mg) and of placebo in a crossover design. All participants were screened to ensure that they were negative for lifetime alcohol and drug addiction, and had been free of substance abuse for at least 6 months. Outcome measures included growth hormone, prolactin, gambling severity, mood, craving and 'high' change scales. A blunted growth hormone response was observed in pathological gamblers compared with healthy controls after Sumatriptan administration. No statistically significant differences were found for prolactin or behavioural measures, except for an increase in anxiety over time in pathological gamblers. These results, together with those obtained in our previous serotoninergic challenge study, document the presence of a serotonergic dysfunction in pathological gamblers similar to that reported in alcoholics.",
keywords = "5-HT1B/1D, alcohol, craving, gambling, growth hormone, Sumatriptan",
author = "Stefano Pallanti and Silvia Bernardi and Andrea Allen and Eric Hollander",
year = "2010",
month = "12",
doi = "10.1177/0269881109106907",
language = "English (US)",
volume = "24",
pages = "1802--1809",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "12",

}

TY - JOUR

T1 - Serotonin function in pathological gambling

T2 - Blunted growth hormone response to Sumatriptan

AU - Pallanti, Stefano

AU - Bernardi, Silvia

AU - Allen, Andrea

AU - Hollander, Eric

PY - 2010/12

Y1 - 2010/12

N2 - Pathological gambling is a disruptive behaviour and an important public health concern that is classified as an impulse control disorder, and is also conceptualized as a prototype of 'behavioural addiction'. Its phenomenology cannot be reduced to a single neurobiological dysfunction; instead, it has been conceived as a complex chain of events in which the serotonergic system (5-HT) has often been suggested as one of the most prominent involved. Acute administration of Sumatriptan, a selective 5-HT1B/1D agonist, has been used to investigate the functional responsivity of 5-HT1B/1D receptors in alcoholics, resulting in a blunted growth hormone response. These findings have been interpreted as being due to the down-regulation of these receptors. However, previous studies could not rule out the possibility that the changes in receptor function were induced by chronic substance exposure. Twenty-two pathological gamblers and 19 healthy control subjects were evaluated in response to double-blind administration of both a single dose of oral Sumatriptan (100 mg) and of placebo in a crossover design. All participants were screened to ensure that they were negative for lifetime alcohol and drug addiction, and had been free of substance abuse for at least 6 months. Outcome measures included growth hormone, prolactin, gambling severity, mood, craving and 'high' change scales. A blunted growth hormone response was observed in pathological gamblers compared with healthy controls after Sumatriptan administration. No statistically significant differences were found for prolactin or behavioural measures, except for an increase in anxiety over time in pathological gamblers. These results, together with those obtained in our previous serotoninergic challenge study, document the presence of a serotonergic dysfunction in pathological gamblers similar to that reported in alcoholics.

AB - Pathological gambling is a disruptive behaviour and an important public health concern that is classified as an impulse control disorder, and is also conceptualized as a prototype of 'behavioural addiction'. Its phenomenology cannot be reduced to a single neurobiological dysfunction; instead, it has been conceived as a complex chain of events in which the serotonergic system (5-HT) has often been suggested as one of the most prominent involved. Acute administration of Sumatriptan, a selective 5-HT1B/1D agonist, has been used to investigate the functional responsivity of 5-HT1B/1D receptors in alcoholics, resulting in a blunted growth hormone response. These findings have been interpreted as being due to the down-regulation of these receptors. However, previous studies could not rule out the possibility that the changes in receptor function were induced by chronic substance exposure. Twenty-two pathological gamblers and 19 healthy control subjects were evaluated in response to double-blind administration of both a single dose of oral Sumatriptan (100 mg) and of placebo in a crossover design. All participants were screened to ensure that they were negative for lifetime alcohol and drug addiction, and had been free of substance abuse for at least 6 months. Outcome measures included growth hormone, prolactin, gambling severity, mood, craving and 'high' change scales. A blunted growth hormone response was observed in pathological gamblers compared with healthy controls after Sumatriptan administration. No statistically significant differences were found for prolactin or behavioural measures, except for an increase in anxiety over time in pathological gamblers. These results, together with those obtained in our previous serotoninergic challenge study, document the presence of a serotonergic dysfunction in pathological gamblers similar to that reported in alcoholics.

KW - 5-HT1B/1D

KW - alcohol

KW - craving

KW - gambling

KW - growth hormone

KW - Sumatriptan

UR - http://www.scopus.com/inward/record.url?scp=78650161981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650161981&partnerID=8YFLogxK

U2 - 10.1177/0269881109106907

DO - 10.1177/0269881109106907

M3 - Article

C2 - 19825906

AN - SCOPUS:78650161981

VL - 24

SP - 1802

EP - 1809

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 12

ER -